XAIRBeyond Air, Inc.

FDA approval decision looms for next-gen device as revenue guidance projects 110% growth.

Beyond Air Inc (XAIR) reports flat Q1 revenue but secures $30 million financing, expands global reach, and reaffirms ambitious 2027 growth targets amid FDA review progress.

Moby summary of Beyond Air, Inc.'s Q1 2027 earnings call

Moby summary of Beyond Air, Inc.'s Q4 2026 earnings call

Beyond Air Inc (NASDAQ:XAIR) is among the best NASDAQ penny stocks to buy according to analysts. On February 20, Beyond Air Inc (NASDAQ:XAIR) commented that it was pleased with a review article that recognized the potential of high-dose nitric oxide as a potential therapy for respiratory illnesses. The peer-reviewed article appeared in a journal of […]

The consensus fair value estimate for Beyond Air has shifted from US$12.33 to US$8.67, signaling a reset in how analysts are framing potential upside. Bulls point to the second generation LungFit PH system and a clearer, though extended, regulatory path as reasons they still see room for upside. Bears, on the other hand, view the lower targets as reflecting a longer and more uncertain route to meaningful sales. As you read on, you will see how these differing views are shaping the evolving...

Beyond Air Inc (XAIR) reports a 105% revenue increase and significant cost reductions, while navigating ongoing financial challenges and FDA approval processes.

Moby summary of Beyond Air, Inc.'s Q3 2026 earnings call